CONDITION

Indolent systemic mastocytosis

Indolent systemic mastocytosis is a long-term condition in which abnormal mast cells build up and release symptom-causing chemicals.

WHAT IT IS
Long-term buildup and activation of abnormal mast cells

BODY SYSTEM
Blood, immune system, skin, bones, and digestive system

MAIN SYMPTOMS
Flushing, itching, digestive upset, severe allergic reactions

WHAT CAUSES IT
Usually an acquired KIT gene change

HOW IT IS DIAGNOSED
Bone marrow biopsy, mast-cell markers, KIT testing, blood tryptase

MAIN TREATMENT
Symptom control, reaction prevention, and targeted therapy

CAN IT BE CURED?
No - symptoms and mast cells can be controlled

IS IT AN EMERGENCY?
Sometimes - breathing trouble or fainting during a reaction

LONG-TERM OUTLOOK
Usually stable, with near-normal lifespan but ongoing symptoms

Overview

Indolent systemic mastocytosis is a long-term condition involving mast cells. Mast cells are immune cells that help the body respond to injury, infection, and allergens. They contain chemicals such as histamine, which can affect the skin, airways, digestive system, heart rate, and blood pressure.

In this condition, abnormal mast cells collect in the bone marrow and sometimes other organs outside the skin. They may also release their chemicals too easily. This can cause symptoms ranging from itching and stomach discomfort to a severe allergic reaction called anaphylaxis.

"Systemic" means that mast cells are present in internal tissues, rather than only in the skin. "Indolent" means that the mast cells are not causing the organ damage seen in advanced forms of systemic mastocytosis. It does not mean that symptoms are always mild. Some

people with indolent systemic mastocytosis have frequent or disabling reactions despite having no organ damage.

The condition is usually lifelong. Symptoms often change over time and may come in episodes. Treatment focuses on controlling symptoms, reducing the risk of serious reactions, protecting bone health, and, for some adults, reducing the number and activity of abnormal mast cells.

Symptoms

Symptoms differ from person to person. Some are present most days, while others occur suddenly after a trigger. A person may have symptoms involving several parts of the body at the same time.

Common symptoms include:

Anaphylaxis is the most serious type of mast-cell reaction. It can cause breathing difficulty, throat or tongue swelling, wheezing, a sudden fall in blood pressure, fainting, or collapse. In mastocytosis, anaphylaxis may sometimes occur without obvious hives or other skin symptoms.

Bone loss can also occur. It may cause no symptoms until a bone breaks, although some people develop persistent back or bone pain.

Possible triggers include insect stings, alcohol, heat, rapid temperature changes, emotional stress, friction on the skin, and certain medicines. Foods trigger symptoms in some people, but there is no single food list that applies to everyone. Episodes can also happen without an identifiable trigger.

These symptoms overlap with many other conditions. Having flushing, hives, digestive problems, or a high tryptase level does not by itself show that you have systemic mastocytosis.

- Flushing, itching, hives, or swelling
- Reddish-brown skin spots that may itch when rubbed
- Abdominal pain, cramping, nausea, diarrhea, or heartburn
- Dizziness, a racing heartbeat, or feeling faint
- Headache, tiredness, difficulty concentrating, or "brain fog"
- Bone or muscle pain

Causes and risk factors

Indolent systemic mastocytosis is usually caused by an acquired change in a gene called KIT . This gene helps control how mast cells grow and survive. The most common change is called KIT D816V. It allows a group, or clone, of abnormal mast cells to build up.

"Acquired" means the change develops in certain cells during a person's life. It is not usually present in every cell and is rarely passed from parent to child. Nothing you ate, did, or were exposed to is known to cause the KIT change.

Some people also have hereditary alpha-tryptasemia, an inherited trait that can raise the baseline blood tryptase level. It may increase the chance or intensity of mast-cell symptoms, but it is separate from systemic mastocytosis.

Triggers such as alcohol, heat, or insect stings do not cause the underlying condition. They may prompt existing mast cells to release chemicals.

Diagnosis

Diagnosis usually involves a specialist in blood conditions, allergy and immunology, or both. No single symptom or routine blood test can confirm indolent systemic mastocytosis.

A blood test may measure baseline serum tryptase , a protein mainly released by mast cells. A persistently raised level can support the diagnosis, but tryptase may be raised for other reasons. Some people with systemic mastocytosis have a level below the usual diagnostic threshold.

A sensitive blood test may look for the KIT D816V gene change. A positive result supports further assessment, but a negative blood result does not always rule out the condition because the altered cells may be difficult to detect in blood.

A bone marrow biopsy is usually central to confirmation. A small sample of marrow is examined for clusters of mast cells, unusual mast-cell shape, specific cell-surface markers, and an activating KIT change. Specialists use an agreed combination of these findings, rather than relying on one result alone.

Other tests may include:

The assessment also looks for signs of organ damage. Indolent systemic mastocytosis is diagnosed when systemic mastocytosis criteria are met but damage caused by mast-cell buildup is absent.

It is different from mast cell activation syndrome, in which episodes of mast-cell mediator release are central to the diagnosis but the abnormal mast-cell collections required for systemic mastocytosis may not be present.

- A complete blood count and liver-related blood tests
- A bone-density scan to look for osteoporosis
- A skin biopsy if mastocytosis-related spots are present
- Imaging or other organ tests when symptoms or examination findings suggest a need

Treatment and management

Treatment is based on your symptoms, previous reactions, bone health, and how much the condition affects daily life. A written plan can explain regular medicines, known triggers, and what to do during a reaction.

Many people use medicines that block or reduce the effects of mast-cell chemicals. These may include H1 antihistamines like cetirizine or loratadine for itching and flushing, H2 antihistamines or acid-suppressing treatment for digestive symptoms, leukotriene-blocking medicines, or a mast-cell stabilizer such as cromolyn for certain digestive symptoms. A specialist may consider other treatments, including omalizumab, for repeated severe reactions or symptoms that remain difficult to control.

People at risk of anaphylaxis are commonly advised to carry prescribed adrenaline, also called epinephrine, autoinjectors. You and people close to you should know where they are and how to use them. Antihistamines do not replace adrenaline during anaphylaxis.

Avoiding a trigger can help when there is a clear and repeatable link. Broad restrictions are usually less useful and may make eating, travel, or medical care unnecessarily difficult. Before surgery, dental treatment, scans using contrast material, or a new medicine, tell the healthcare team that you have systemic mastocytosis. Premedication is not automatically required for every procedure; the plan is usually based on your reaction history and the procedure involved.

Avapritinib is a targeted medicine approved in some countries for adults with indolent systemic mastocytosis. It blocks abnormal KIT activity and can reduce mast-cell burden and symptoms. It may be considered when symptoms remain significant despite supportive treatment. It requires specialist assessment and monitoring because it can cause side effects and interact with other medicines.

Stronger treatments used to reduce blood-cell production are generally reserved for advanced systemic mastocytosis, not routine indolent disease.

Bone-density testing may be repeated when appropriate. Osteoporosis is treated according to its severity and fracture risk, alongside individual advice about vitamin D, calcium, exercise, smoking, and alcohol.

Complications

Anaphylaxis is the main immediate complication. Insect stings are an important trigger for some people, although reactions may also follow medicines, foods, or no clear trigger. If testing confirms an insect-venom allergy, venom immunotherapy may be considered to lower the risk from future stings.

Long-term complications can include osteoporosis and fractures, especially involving the spine. Persistent diarrhea, abdominal discomfort, poor sleep, fatigue, and fear of reactions may also affect nutrition, employment, travel, relationships, and emotional wellbeing.

Indolent systemic mastocytosis only uncommonly changes into a more advanced form. New blood-count abnormalities, increasing liver or spleen size, unexplained weight loss, or a major and persistent change in symptoms may lead to reassessment. These findings can have many causes and do not automatically mean the condition has progressed.

Prevention

There is no known way to prevent indolent systemic mastocytosis or the acquired KIT gene change that usually causes it.

You may be able to prevent some symptom episodes and complications by identifying your own reliable triggers, taking prescribed preventive medicines, carrying emergency adrenaline when advised, and following up on bone health.

Avoiding every possible trigger is neither practical nor necessary. A symptom diary can sometimes reveal patterns, but a trigger should not be assumed from a single episode.

Living with it and what to expect

Indolent systemic mastocytosis is usually a lifelong condition. The abnormal mast cells generally remain present even when symptoms are well controlled. Symptoms may improve, worsen, or change over months and years, and quiet periods do not necessarily mean the condition has gone away.

Most people with the indolent form do not develop organ damage from mast-cell buildup, and life expectancy is often close to that of the wider population. The effect on quality of life can still be substantial, particularly when reactions are unpredictable, digestive symptoms continue, or fatigue and concentration problems interfere with daily activities.

Follow-up may include reviewing reactions and medicines, checking blood counts and tryptase, and assessing bone health. The schedule is usually based on your symptoms and previous results rather than being the same for everyone.

Practical preparation can make daily life easier. This may include carrying an emergency plan, keeping adrenaline accessible, wearing medical identification, and giving schools, workplaces, or travel companions clear instructions. Emotional support may also help if fear of a reaction is limiting activities.

Pregnancy is possible for many people with indolent systemic mastocytosis. Symptoms may improve, worsen, or stay similar. Medication and delivery planning should be reviewed in advance with the relevant specialists.

When to get medical help

Call emergency services if you develop signs of anaphylaxis, including:

If you have been prescribed an adrenaline autoinjector, use it immediately according to your emergency plan, then call emergency services. Symptoms can return after seeming to improve, so medical assessment is still needed.

Seek prompt medical advice for a major change in your usual symptoms, repeated reactions needing adrenaline, severe or persistent abdominal symptoms, an unexplained fracture, new persistent bone pain, unusual bleeding, or unexplained weight loss.

Routine follow-up is the right place to discuss ongoing flushing, itching, digestive symptoms, fatigue, medicine side effects, trigger patterns, bone-density results, and whether your emergency plan remains suitable.

- Trouble breathing, wheezing, or throat or tongue swelling
- Fainting, collapse, confusion, or severe weakness
- A sudden combination of skin, breathing, digestive, or circulation symptoms

Common questions

Is indolent systemic mastocytosis a type of cancer?

It is a clonal blood condition, meaning the abnormal mast cells come from one changed cell, and it is medically classified as a blood-cell neoplasm. However, the indolent form usually behaves very differently from an aggressive cancer. It often remains stable and does not cause organ damage.

Will it turn into aggressive systemic mastocytosis?

Progression is uncommon, but it is possible. Routine monitoring looks for lasting changes in symptoms, blood counts, or organ function. A temporary flare does not by itself mean the condition has progressed.

Do I need to follow a low-histamine diet?

There is no universal mastocytosis diet. Evidence for broad low-histamine diets is limited, and unnecessary restrictions may lead to poor nutrition. It is usually more useful to avoid foods that repeatedly cause your own symptoms and to discuss major dietary restrictions with a qualified professional.

Can indolent systemic mastocytosis be inherited?

Most cases are not inherited because the KIT change is acquired in a limited group of cells. Rare familial cases and separate inherited traits, such as hereditary alpha-tryptasemia, can occur.

Can the condition go away?

The underlying mast-cell clone usually remains throughout life. Symptoms may become much less active for long periods, especially with effective treatment, but this is not the same as a cure.

Can I exercise and travel?

Many people can exercise and travel with planning. Heat, sudden temperature changes, or intense exertion trigger symptoms in some people, so gradual activity and ready access to emergency medicines may help. Keep adrenaline in your hand luggage and check storage instructions when travelling.

Sources

- Valent P, Akin C, Hartmann K, and colleagues. "Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal." HemaSphere . 2021;5(11):e646.
- Pardanani A. "Systemic Mastocytosis in Adults: 2023 Update on Diagnosis, Risk Stratification and Management." American Journal of Hematology . 2023.
- Castells M, Butterfield J. "Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management." Journal of Allergy and Clinical Immunology: In Practice . 2019;7(4):1097-1106.

- Gotlib J, Reiter A, Radia DH, and colleagues. "Avapritinib versus Placebo in Indolent Systemic Mastocytosis." NEJM Evidence . 2023.
- US Food and Drug Administration. AYVAKIT (avapritinib) Prescribing Information . Blueprint Medicines Corporation.
- National Cancer Institute. Mastocytosis Treatment (PDQ®)-Patient Version . US National Institutes of Health.